Large Cap
Diagnostics & Research
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
Danaher
DHR
$152B
| $152B | $215.97 | 0.4% |
|
2
Natera
NTRA
$48.5B
| $48.5B | $336.71 | 2.74% |
|
3
Agilent Technologies
A
$43.7B
| $43.7B | $154.77 | 0.87% |
|
4
Idexx Laboratories
IDXX
$43.3B
| $43.3B | $550.01 | 1.7% |
|
5
IQVIA
IQV
$42.7B
| $42.7B | $259.42 | 0.32% |
|
6
Waters Corp
WAT
$40.7B
| $40.7B | $414.44 | 0.9% |
|
7
Illumina
ILMN
$34B
| $34B | $224.99 | 0.79% |
|
8
Mettler-Toledo International
MTD
$28.1B
| $28.1B | $1,402.25 | 0.24% |
|
9
Labcorp
LH
$27.4B
| $27.4B | $337.68 | 0.49% |
|
10
Quest Diagnostics
DGX
$27B
| $27B | $244.51 | 0.26% |
|
11
Guardant Health
GH
$22.1B
| $22.1B | $164.92 | 1.07% |
|
12
Medpace
MEDP
$17.1B
| $17.1B | $614.06 | 0.96% |
|
13
Charles River Laboratories
CRL
$14.2B
| $14.2B | $297.64 | 0.31% |
|
14
Revvity
RVTY
$13.9B
| $13.9B | $124.84 | 1.5% |
|
15
Icon
ICLR
$13B
| $13B | $168.91 | 2.63% |
|
Large Cap Diagnostics & Research Stocks at a Glance
Diagnostics and research companies run laboratory testing, imaging, and analytical services, and supply the instruments behind them. Testing volumes are recurring and largely non-discretionary, while research-tools demand follows pharma and academic R&D budgets.
There are 15 large cap Diagnostics & Research stocks — companies in the Diagnostics & Research industry with a market cap between $10B and $200B — worth a combined $568B.
The largest by market cap are Danaher (DHR) at $152B, Natera (NTRA) at $48.5B and Agilent Technologies (A) at $43.7B.
Among institutional investors, Guardant Health (GH) drew the most net new fund positions in Q2 2026: 158 funds opened new positions, taking total fund holders up 112 (23%) quarter-over-quarter.
- Combined market cap: $568B across 15 stocks.
- Large Cap: market cap between $10B and $200B.
- Largest constituent: Danaher (DHR), $152B market cap.
- Most net new fund positions in Q2 2026: Guardant Health (GH), +112 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.